SLC2A1 and Miyoshi myopathy: It was shown that MM cell lines expressing high levels of GLUT1, and consequently increased glucose uptake, respond synergistically to the combinatorial treatment of bortezomib with the GLUT1 inhibitor STF-31 [112].